Cancer Research at Novartis Oncology
This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room
Research
Please visit the Novartis Oncology Pipeline, which includes compounds in all phases of development, starting with preclinical studies through large Phase III randomized trials.
Everolimus Press Releases
EVEROLIMUS CONTACT
Heather Bochner
Novartis Oncology Global Public Relations
office +1 862-778-5092
Heather.Bochner@novartis.com
Nicole Riley
Novartis Oncology Global Public Relations
office +1 862-778-3110
Nicole.Riley@novartis.com
Everolimus Videos
26-Apr-2012
Kari Luther Rosbeck, President and CEO, and Dr. Steve Roberds, Chief Scientific Officer of the Tuberous Sclerosis Alliance
Everolimus Materials
-
26-Apr-2012
EXIST-2 Trial Fact Sheet -
26-Apr-2012
Renal Angiomyolipoma Fact Sheet -
31-Jan-2012
TSC Patient Journey Infographic -
02-Dec-2011
mTOR Infographic -
02-Dec-2011
Breast Cancer Heritage Fact Sheet -
23-Sep-2011
Advanced Breast Cancer Infographic -
23-Sep-2011
TAMRAD Trial Fact Sheet -
08-Sep-2011
Tuberous Sclerosis Complex Fact Sheet
INC424 Press Releases
INC424 CONTACT
Gloria Vanderham
Novartis Oncology Global Public Relations
office +1 862-778-4268
Gloria.Vanderham@novartis.com
INC424 Materials
-
Apr-2012
Myelofibrosis Reference Guide for Journalists -
Dec-2011
JAK-STAT Pathway Backgrounder -
May-2011
COMFORT-I Clinical Trial Fact Sheet -
May-2011
COMFORT-II Clinical Trial Fact Sheet
SEARCH OUR WEBSITES
ABOUT NOVARTIS ONCOLOGY
We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.